taladegib

Overview

Taladegib is an investigational SMO (Smoothened) inhibitor targeting the Hedgehog signaling pathway. It is evaluated in solid tumors with PTCH1 mutations, including nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Taladegib SMO inhibitor (Hedgehog pathway) evaluated in phase II for solid tumors with PTCH1 mutations, including NPC; PTCH1 mutation is listed as a molecularly targeted opportunity in NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.